Free Trial

Sarepta Therapeutics (SRPT) Stock Price, News & Analysis

Sarepta Therapeutics logo
$118.97 -0.50 (-0.42%)
(As of 12/20/2024 05:31 PM ET)

About Sarepta Therapeutics Stock (NASDAQ:SRPT)

Key Stats

Today's Range
$118.56
$121.00
50-Day Range
$104.54
$137.94
52-Week Range
$89.92
$173.25
Volume
1.95 million shs
Average Volume
1.22 million shs
Market Capitalization
$11.36 billion
P/E Ratio
95.18
Dividend Yield
N/A
Price Target
$178.71
Consensus Rating
Moderate Buy

Company Overview

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Sarepta Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
95th Percentile Overall Score

SRPT MarketRank™: 

Sarepta Therapeutics scored higher than 95% of companies evaluated by MarketBeat, and ranked 48th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sarepta Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 19 buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Sarepta Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Sarepta Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Sarepta Therapeutics are expected to grow by 365.74% in the coming year, from $2.16 to $10.06 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sarepta Therapeutics is 95.18, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.80.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sarepta Therapeutics is 95.18, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 87.11.

  • Price to Book Value per Share Ratio

    Sarepta Therapeutics has a P/B Ratio of 12.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.09% of the outstanding shares of Sarepta Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Sarepta Therapeutics has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in Sarepta Therapeutics has recently increased by 15.48%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Sarepta Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Sarepta Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.09% of the outstanding shares of Sarepta Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Sarepta Therapeutics has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in Sarepta Therapeutics has recently increased by 15.48%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Sarepta Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for Sarepta Therapeutics this week, compared to 11 articles on an average week.
  • Search Interest

    Only 19 people have searched for SRPT on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
  • MarketBeat Follows

    Only 6 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sarepta Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,516,220.00 in company stock.

  • Percentage Held by Insiders

    Only 7.70% of the stock of Sarepta Therapeutics is held by insiders.

  • Percentage Held by Institutions

    86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Sarepta Therapeutics' insider trading history.
Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Stock News Headlines

Crypto’s hidden gem + greatest crypto bull run in history = $$$?
You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.
Sarepta Therapeutics' (SRPT) Sell Rating Reaffirmed at HC Wainwright
Here are highlights from Thursday’s Analyst Blog:
Sarepta completes enrollment in the EMERGENE study of SRP-9003
See More Headlines

SRPT Stock Analysis - Frequently Asked Questions

Sarepta Therapeutics' stock was trading at $96.43 at the beginning of 2024. Since then, SRPT stock has increased by 23.4% and is now trading at $118.97.
View the best growth stocks for 2024 here
.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) released its quarterly earnings data on Wednesday, August, 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.06. The business's revenue for the quarter was up 38.9% on a year-over-year basis.

The following companies are subsidiaries of Sarepta Therapeutics: Myonexus Therapeutics, Eisai, Sarepta Securities Corp., Sarepta Therapeutics Three LLC, and ST International Holdings Two Inc..

Sarepta Therapeutics' top institutional investors include Janus Henderson Group PLC (4.56%), Wellington Management Group LLP (2.85%), Geode Capital Management LLC (1.78%) and Jacobs Levy Equity Management Inc. (0.79%). Insiders that own company stock include Douglas S Ingram, Michael Andrew Chambers, Richard Barry, Ian Michael Estepan, Hans Lennart Rudolf Wigzell, Bilal Arif, Dallan Murray, Ryan Edward Brown, Stephen Mayo and Kathryn Jean Boor.
View institutional ownership trends
.

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sarepta Therapeutics investors own include Zomedica (ZOM), NVIDIA (NVDA), Humana (HUM), American Water Works (AWK), Meta Platforms (META), Voyager Therapeutics (VYGR) and Waste Connections (WCN).

Company Calendar

Last Earnings
8/07/2024
Today
12/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SRPT
Previous Symbol
NASDAQ:AVII
Employees
1,314
Year Founded
1980

Price Target and Rating

Average Stock Price Target
$178.71
High Stock Price Target
$230.00
Low Stock Price Target
$75.00
Potential Upside/Downside
+50.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
22 Analysts

Profitability

Net Income
$-535,980,000.00
Pretax Margin
7.89%

Debt

Sales & Book Value

Annual Sales
$1.64 billion
Book Value
$9.19 per share

Miscellaneous

Free Float
88,165,000
Market Cap
$11.36 billion
Optionable
Optionable
Beta
0.77

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:SRPT) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners